Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective by Holmes, M. et al.
	



	

	



 !
∀
	

	
				
 

!
∀#∃#%#&&∀
#∋() ∗+	
		∀	
+	
,∀&	
+−,.∋&/

/0+1∋2

3	3∀
∋

∀#44(4∗))5)44,&&−6 567 
		8

/   69 )645 95 )445:




#

	;	

				

Alteplase for the treatment of acute ischaemic stroke: A NICE 
Single Technology Appraisal; an Evidence Review Group 
perspective. 
 
Short header: Alteplase for acute ischaemic stroke. 
 
 
 
Michael Holmes1* 
Sarah Davis1 
Emma Simpson1 
1School of Health and Related Research, University of Sheffield, Sheffield, S1 4DA. 
*Corresponding author 
Tel: 0114 2220745 
Fax: 0114 2724095 
Email: m.w.holmes@shef.ac.uk 
 
 
 
Word count:5226 
  
 2 
 
Abstract 
Background: The National Institute for Health and Care Excellence (NICE) invited 
Boehringer Ingelheim GmbH, the manufacturer of alteplase, to submit evidence for the clinical 
and cost-effectiveness of alteplase for the prevention of strokes as part of 1,&(¶V single 
technology appraisal (STA) process. The comparator was standard medical and supportive 
management that does not include alteplase, as identified in the scope issued by NICE. The 
School of Health and Related Research at the University of Sheffield were commissioned to 
act as the Evidence Review Group (ERG).  This paper provides a description of the company 
VXEPLVVLRQWKH(5*UHYLHZDQG1,&(¶VVXEVHTXHQWGHFLVLRQV 
Objective: To critique independently the evidence submitted for consideration by the NICE 
Appraisal Committee (AC). 
Methods: The ERG produced a critical review of the evidence for the clinical and cost 
effectiveness of the technology based upon the PDQXIDFWXUHUV¶ submission (MS) to NICE.   
Results: Clinical effectiveness evidence for alteplase was derived from 5 trials. Estimates of 
clinical effectiveness were provided in the submission for three treatment windows: 0-4.5 
hours, 0-3 hours and 3-4.5 hours from symptom onset. For the 0-3 hour treatment window, no 
additional trials were identified to those included in the original STA (TA 122). The ECASS III 
randomised controlled trial (RCT) provided the main evidence for the 3-4.5 hour treatment 
window. In this trial, death or dependency at three months follow-up did not show a 
statistically significant treatment effect, although the midpoint favoured alteplase. In terms of 
safety, there was no statistically significant difference in all cause mortality at 3 months, but 
there was a significantly increased risk of symptomatic intracranial haemorrhage (SICH). 
Evidence for the 0-4.5 hour treatment window was obtained from a meta-analysis of 3 trials 
which indicated that the reduction of death and dependency, due to alteplase, was statistically 
significant, however there was also a significant increase in SICH. The economic model 
described in the MS was considered by the ERG to meet the NICE reference case. The 
model structure was considered to be appropriate and the ERG has no major concerns 
regarding the selection of data used within the model. The incremental cost-effectiveness 
ratios for the 0-3, 3-4.5 and 0-4.5 hour treatment windows were all well below accepted 
willingness to pay thresholds. 
Conclusion: The ERG had no major concerns regarding the completeness of the 
submission or the robustness of the evidence presented. The RCTs included were generally 
of good quality. The main area of uncertainty with regard to clinical effectiveness related to 
differences in stroke severity at baseline, which potentially favoured alteplase, in two of the 
three key trials.  
In the cost-effectiveness analysis the main driver of decision uncertainty was the lack of 
precision around the efficacy estimates. However, for all of the treatment windows 
considered, alteplase was found to be cost-effective compared with standard treatment. 
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Key points for decision makers 
x Alteplase administered between 0 and 4.5 hours after onset of stroke symptoms was 
considered to be an effective treatment for acute ischaemic stroke because it 
decreased the probability of death or dependence. 
x A significantly higher proportion of patients in the alteplase arm had symptomatic 
intracranial haemorrhage within 10 days compared with the placebo arm for the 0 to 
4.5 hour treatment window. 
x The balance of risks and benefits may be slightly different depending on whether 
alteplase is administered within 0 to 3 hours or within 3 to 4.5 hours of symptom 
onset. 
x Alteplase either dominated standard care or had an incremental cost-effectiveness 
ratio (ICER) below £10,000 per quality adjusted life years (QALY) gained depending 
on the time-to-treatment window considered. 
x Extension of the time window for treatment should not diminish the urgency with 
which people suspected of having an acute ischaemic stroke should be treated. 
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1. ,QWURGXFWLRQ 
Health technologies must be shown to be clinically effective and to represent a cost-effective 
use of National Health Service (NHS) resources to be recommended for use within the NHS 
in England and Wales. The National Institute for Health and Care Excellence (NICE) is an 
independent organisation responsible for providing national guidance on promoting good 
health and preventing and treating ill health in priority areas with significant impact. The NICE 
single technology appraisal (STA) process usually covers new technologies soon after the UK 
market authorisation and is specifically designed for the appraisal of a single health 
technology, within a single indication [1]. 
Within the STA process, the manufacturers provide NICE with a written submission, alongside 
a mathematical model that summarises the PDQXIDFWXUHU¶V estimates of the clinical and cost 
effectiveness of the technology. This submission is reviewed by an external academic 
organisation independent of NICE [the Evidence Review Group (ERG)], which consults with 
clinical specialists, and an ERG UHSRUWLVSURGXFHG$IWHUFRQVLGHUDWLRQRIWKHPDQXIDFWXUHUV¶
submission, the ERG report and testimony from experts and other stakeholders, the NICE 
Appraisal Committee usually formulates the preliminary guidance, the Appraisal Consultation 
Document (ACD), which indicates the initial decision of the Appraisal Committee regarding 
the recommendation (or not) of the intervention. 
Stakeholders are then invited to comment on the submitted evidence and the ACD, after 
which a subsequent ACD may be produced or a Final Appraisal Determination (FAD) is 
issued, which is open to appeal. An ACD is not produced when the intervention is 
recommended without restriction; in this instance, a FAD is directly produced. 
In June 2007 NICE issued guidance recommending alteplase for the treatment of acute 
ischaemic stroke (AIS) within 3 hours of the onset of stroke symptoms.[2] On 14 March 2012 
the manufacturer received approval from the Medicines and Healthcare products Regulatory 
Agency (MHRA) extending the use of alteplase to within 4.5 hours of the onset of symptoms. 
The previous NICE guidance has therefore been reviewed to include treatment with alteplase 
up to a 4.5 hour window and this paper presents a summary of that review. Full details of all 
the relevant appraisal documents (including the appraisal scope, ERG report, manufacturers 
and consultee submissions, FAD, and comments on each of these) can be found on the NICE 
website at:http://guidance.nice.org.uk/TA264. 
2. 7KHFOLQLFDOFRQGLWLRQDQGEDFNJURXQG 
Stroke is a serious medical condition in which the blood supply to the brain is disrupted, 
potentially resulting in disability and mortality. The World Health Organisation (WHO) defined 
stroke as rapidly developing clinical signs of focal (sometimes global) disturbance of cerebral 
function, lasting more than 24 hours or leading to death with no apparent cause other than 
that of vascular origin [3]. Symptoms of stroke include numbness, disrupted vision, slurred 
speech, confusion and headache. There are two major types of stroke: ischaemic stroke 
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which accounts for 85% of strokes, and is caused by a disrupted blood supply due to 
narrowing or blockage of the circulatory system; and haemorrhagic stroke which accounts for 
about 15% of strokes and is due to blood loss in the brain from arteriolar hypertensive 
disease resulting in neurological damage. It is often difficult for clinicians to identify the 
particular stroke subtype without access to evidence from an autopsy or brain scan, and 
therefore a large number oI GHDWKV DUH UHFRUGHG DV HLWKHU µXQVSHFLILHG VWURNH¶ RU µRWKHU
FDUGLRYDVFXODUGLVHDVH¶ [4].  
Stroke is the second largest cause of death in the United Kingdom after heart disease [5]. 
Over 56,000 deaths due to stroke were recorded in England and Wales in 1999, which 
represents 11% of all deaths recorded that year [6]. Annually about 110,000 people in 
England have a first or recurrent stroke, [7] and a further 54 000 individuals have a transient 
ischaemic attack (TIA) in England each year [8]. 
More than 900,000 people in England are living with the effects of stroke, with half of these 
being dependent on other people for help with everyday activities [8].  Stroke causes a 
greater range of disabilities than any other condition, [9]and causes secondary medical 
problems, including dementia, depression, epilepsy, falls and fractures which place a 
considerable burden on the economy in England, resulting in an estimated annual direct cost 
to the National Health Service of £2.8 billion in 2001 [6]. 
3. 7KHWHFKQRORJ\ 
Alteplase (Actilyse, Boehringer Ingelheim) is a tissue plasminogen activator manufactured by 
recombinant DNA technology. It activates the production of plasmin from its precursor 
plasminogen. Plasmin is an enzyme which degrades fibrin clots. The aim of treatment is to 
reduce the impact of ischaemia by restoring blood flow through the occluded (or blocked) 
artery. It is administered by intravenous infusion. 
A UK licence for the use of alteplase within a 0-3 hour administration time period from the 
onset of symptoms for the treatment of AIS was granted in September 2002. The 
manufacturers received licence approval from the MHRA for alteplase use to be extended to 
4.5 hours from the onset of symptoms on 14th March 2012. 
The cost of alteplase was £135 per 10-mg pack, £180 per 20-mg pack and £300 per 50-mg 
SDFNH[FOXGLQJ9$7µ%ULWLVKQDWLRQDOIRUPXODU\¶>%1)@HGLWLRQ at the time of appraisal by 
NICE [10]. The cost per course of treatment depends on the body weight of the patient, and 
can range from £300 to £600 based on a recommended dose of 0.9 mg per kilogram of body 
weight. Costs may vary in different settings because of negotiated procurement discounts.  
As the use of alteplase is solely additive and not intended to replace any routine practice the 
correct comparator is placebo or standard medical and supportive management without 
thrombolysis. This is appropriate given that no thrombolytic treatment other than alteplase is 
licensed in the UK for this purpose. As the most important therapy in AIS is restoration of the 
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blood supply to the affected area of the brain [11], other stroke treatment or prevention 
therapies, which function in different ways, would not be relevant comparators. 
Alteplase should only be administered after exclusion of intracranial haemorrhage by a cranial 
computerized tomography (CT) scan or other diagnostic imaging method sensitive for the 
presence of haemorrhage. 
The most common complication during alteplase therapy is bleeding. Should serious bleeding 
occur in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial), alteplase 
therapy should be discontinued immediately, along with any concomitant therapy with 
heparin.  
4. 7KHLQGHSHQGHQW(5*UHYLHZ 
The manufacturer provided a submission to NICE on the use of alteplase within its licensed 
indication for the treatment of acute ischaemic stroke. The comparator was standard medical 
and supportive management that does not include alteplase as identified in the scope [12] 
issued by NICE. The ERG report comprised a critical review of the evidence for the clinical 
and cost effectiveness of the technology based upon the manufacturer¶s submission (MS) to 
NICE. The review embodied three aims:  
x To assess whether the MS conformed to the methodological guidelines issued by 
NICE; 
x To assess whether the PDQXIDFWXUHU¶V interpretation and analysis of the evidence 
was appropriate; 
x To indicate the presence of other sources of evidence or alternative interpretations of 
the evidence that could help to inform NICE guidance. 
The ERG conducted a detailed critical appraisal of the MS. As part of this process the ERG 
had the opportunity to obtain clarification on specific points in the MS. The ERG were satisfied 
with the responses received from the manufacturer which included revised models, submitted 
after the ERG identified a summation error in the results sheet of the original model, and 
some additional sensitivity analyses. 
4.1. Clinical evidence  
The MS identified 10 randomised controlled trials of alteplase in AIS, of which five provided 
relevant data and were included in either the main analyses or the sensitivity analyses [13±
18]. The time-frame for onset to treatment varied across the trials with no single trial providing 
a randomised comparison of treatment within 0 to 4.5 hours of symptom onset. Estimates of 
clinical effectiveness were provided in the submission for three treatment windows: 0 to 4.5 
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hours, 0 to 3 hours and 3 to 4.5 hours from symptom onset. This subgroup analysis 
examining symptom onset to treatment time was pre-specified in the scope. 
The main outcomes addressed in detail within the submission were death, death or 
dependency and symptomatic intracranial haemorrhage (SICH). Dependency was defined as 
a score of 3 to 5 on the Modified Rankin Scale (mRS). The composite outcome of death or 
dependency is assumed to capture both the treatment effect of alteplase and the adverse 
impact of any treatment related SICH. 
For the 0-3 hour treatment window, there were no additional trials identified to those included 
in the 2007 NICE STA of alteplase for the treatment of acute ischaemic stroke (TA122) [2]. 
The main trials providing evidence for the 0 to 3 hour treatment window were the NINDS trial 
[13], which examined treatment within 3 hours and the ECASS II trial [14], which stratified 
randomisation by onset to treatment time providing a pre-specified subgroup analysis for 
patients treated within 3 hours. The inclusion of further evidence from the ATLANTIS trials 
[15, 16] (which did not stratify randomisation by 0-3 hours) was explored in a sensitivity 
analysis although these estimates were informed by an ad-hoc subgroup analysis. Death or 
dependency at three months follow-up significantly favoured alteplase, relative risk (RR) 0.81 
(95%CI 0.72-0.92) p=0.002, by random-effects meta-analysis of the two main trials which 
included 393 participants allocated to alteplase, and 389 to placebo.  In terms of safety, there 
was no statistically significant difference in all cause mortality at 3 months in either the fixed 
or random effects meta-analysis. There was a significantly increased risk of SICH, RR 4.90 
(95%CI 1.90-12.61) p=0.001, by fixed effects meta-analysis, but the difference was not 
statistically significant by random effects meta-analysis, RR 3.94 (95%CI 0.61-25.47) p=0.15. 
The results of the sensitivity analysis incorporating data from the ATLANTIS trials [15, 16] 
were similar, although in this analysis the RR for SICH was significantly higher for both the 
fixed and random effects meta-analysis. 
For the 3-4.5 hour treatment window, the main evidence used in the MS was the ECASS III 
RCT [17, 18]. This RCT included 418 alteplase and 403 placebo participants.  In the ECASS 
III trial, death or dependency at three months follow-up did not show a statistically significant 
treatment effect, RR 0.87 (95%CI 0.73-1.05) p=0.14, although the midpoint favoured 
alteplase. In terms of safety, there was no statistically significant difference in all cause 
mortality at 3 months, but there was a significantly increased risk of SICH, RR 4.82 (95%CI 
1.06-21.87) p=0.04. The inclusion of further evidence from the ECASS II [14] and ATLANTIS 
trials [15, 16] (which did not stratify randomisation according to treatment within 3-4.5hours of 
symptom onset)was explored in a sensitivity analysis, although this relied on ad-hoc subgroup 
analyses from these trials. 
Considering the 0-4.5 hour treatment window, random-effects meta-analysis of the two main 
trials of 0-3 hours, (n=393 alteplase and n=389 placebo), and the main trial of 3-4.5 hours, 
(n=418 alteplase and n=403 placebo), showed a RR for death or dependency of 0.83 (95%CI 
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0.75-0.92) p=0.0006, significantly favouring alteplase. Again, there was no statistically 
significant increase in all cause mortality at 3 months, but there was a significantly increased 
risk of SICH. Heterogeneity between the three studies was low (I2< 25%) for the outcomes of 
death and death or dependency, but higher for SICH (I2=42%). However, the heterogeneity 
across the three studies was lower than that seen when pooling data from the two trials 
examining 0-3 hours, as the results of the ECASS III study [17] were closer to those of the 
large NINDS study [13] than the small subgroup analysis of the ECASS II study [14]. 
4.1.1. Critique of clinical evidence and interpretation 
The ERG believes that all relevant RCTs were identified in the MS. The evidence submitted in 
the MS reflected the decision problem within the NICE final scope with all included trials 
providing relevant data.  The analyses presented were restricted to participants for whom 
alteplase was administered within 4.5 hours of symptom onset, and so this accurately 
reflected the NICE scope. The RCTs included were generally of good quality with regard to 
randomisation and having blinded outcome assessors. However, both the NINDS, one of the 
two main trials for 0-3 hours, and the trial contributing most participants for 0-3 hours, and the 
ECASS III RCT, providing the main evidence for 3-4.5 hours, had imbalances in baseline 
stroke severity favouring alteplase. There is disagreement in the literature as to whether the 
imbalance in the NINDS trial would significantly skew treatment effect outcomes [19,20]. All of 
the RCTs used appropriate statistical techniques and conducted an intention-to-treat analysis. 
The meta-analysis approach was appropriate and both fixed and random effects analyses 
were provided. The ERG would agree with the exclusion of data derived from ad-hoc 
subgroup analyses from the base-case meta-analyses. With regard to the pooling of data 
across different treatment windows, a pooled analysis [21] of 3670 patients from 8 RCTs, 
which examined the interaction between treatment effect and onset to treatment time, found 
that there was a significant interaction for the outcomes of death and dependency (mRS of 
greater than 1) and mortality, but not for SICH. (It should be noted that not all of the 8 RCTs 
included in the pooled analysis examined the use of alteplase in line with its UK marketing 
authorisation.) However, the adjusted odds ratios provided by the pooled analysis [21] 
supports the meta-analysis of the RCT data presented within the MS, in showing a significant 
treatment effect for dependency and a non-significant difference in mortality at three months 
for both the 0 to 3 and 3 to 4.5 hour onset to treatment windows. 
4.2. Cost-effectiveness evidence  
The economic model submitted was an updated version of a published Health Technology 
Appraisal (HTA) which also formed the basis of Boehringer ,QJHOKHLP¶VVXEPLVVLRQWR7$ 
[2]. The model compared treatment with alteplase alongside standard care against a 
comparator of standard care alone. Estimates of cost-effectiveness were provided for three 
treatment windows: 0 to 4.5 hours, 0 to 3 hours and 3 to 4.5 hours from symptom onset. The 
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models for these three treatment windows used different estimates of treatment effect but 
were otherwise equivalent.  
The efficacy estimates used in the basecase scenarios for the three treatment windows were 
limited to the NINDS (0-3 hours), ECASS II (0-3 hours) and ECASS III (3-4.5 hours) trials as 
data were available from these trials for the required treatment windows using either the 
whole trial population or a pre-specified subgroup with randomisation stratified appropriately. 
Sensitivity analyses were conducted using alternative efficacy estimates which incorporated 
ad-hoc subgroup analyses of the ATLANTIS trials and ECASS II trials. 
Treatment effect was captured by modelling the distribution of patients between the health 
states dependent, independent and dead at 6 months following treatment. This was based on 
efficacy outcomes from the trials at 3 months. The only trial providing longer-term follow-up, 
from a population meeting the licensed indication was NINDS. Results from this trial support 
the maintenance of benefits from 3 to 6 months and this was considered clinically reasonable. 
Dependency is defined as a score of 3 to 5 on the mRS. These outcomes were assumed to 
capture both the impact of alteplase on stroke severity and the impact of any SICH following 
alteplase. The probabilities of transitions between the health states beyond 6 months were 
assumed to be equivalent between the two treatment arms and were based on data from the 
Lothian Stroke Registry (LSR). After the first year, patients remained in the same health state 
until they either experienced a recurrent stroke or died. Age-specific general population 
mortality risks were applied after the first year. These were adjusted to account for the higher 
risk of mortality following stroke. A fixed annual mortality risk was applied after recurrent 
stroke. 
Costs and health-related quality of life estimates applied to the health states were based on 
published estimates from the UK population [22-24]. The cost of alteplase was dependent on 
the body weight of the patient. The manufacturer assumed that the mean body weight (76kg) 
of patients in the SITS-MOST [24] study was representative of the average stroke patient in 
UK clinical practice. Patients were given 0.9 mg of alteplase per 1 kg of body weight, and so 
the dose received by a patient weighing 76kg was 68.4mg (76kg * 0.9mg/kg). The cost of 
68.4mg alteplase was based on a 50mg pack (£300) plus a 20mg pack (£180) and was thus 
estimated to be £480. The cost could UDQJHIURPWRGHSHQGLQJRQWKHLQGLYLGXDO¶V
weight and the average cost is likely to be higher than £480 as any patient weighing over 
78kgs would require two 50mg packs. However, a univariate sensitivity analysis covering this 
range of cost was presented in the MS. The source of the price of the packs was not 
referenced in the MS but the prices cited were consistent with those given in the British 
National Formulary at the time of the appraisal [10].  
Estimates of extra staffing requirements associated with administering alteplase were based 
upon the resource use figures described by Sandercock et al.,[20]. These were considered 
UHDVRQDEOH E\ WKH (5*¶V clinical advisors. The cost of additional staffing to administer 
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alteplase, based on the above resource use and costed from the Personal Social Services 
Research Unit (PSSRU) unit costs [23], was estimated to be £1,316 per patient.  
The health related quality of life values used for the dependent and independent stroke states 
were based on the responses to the EuroQoL quality of life questionnaire of a sample of 147 
LSR patients as described in Sandercock et al., [20]. These values were 0.74 (95% CI 0.69-
0.79) and 0.38 (95% CI 0.29-0.47) for the independent and dependent stroke states, 
respectively. It appears reasonable to the ERG that the manufacturer has used the LSR study 
utilities as these values were elicited from a UK population, and were measured and valued 
using the EuroQol as per the NICE reference case [25]. 
Costs and quality adjusted life years (QALYs) were estimated using a life-time horizon with 
future costs and benefits discounted at 3.5%. The economic perspective was the NHS and 
the Personal Social Services (PSS). Costs were adjusted to 2012/13 levels using an inflation 
rate of 3% (based on the Pay & Prices index from PSSRU 2011 [23]). 
The impact of parameter uncertainty was estimated in a probabilistic sensitivity analysis. 
Scenario analyses were run on key parameters. 
The ICER (cost per QALY gained) for treatment within 0 to 4.5 hours from symptom onset 
was estimated at £2,296 when using the mean costs and QALYs from the probabilistic 
analysis. However, this cost-effectiveness estimate relied on combining efficacy estimates for 
treatment across two different time windows. When considering treatment within 3 hours, 
alteplase dominated standard care as the mean QALYs gained are greater and the mean cost 
is lower than for standard care. However, the ICER for treatment within of 3 to 4.5 hours of 
symptom onset was less favourable at £6,169 per QALY. 
The cost-effectiveness results were generally robust under the sensitivity analyses 
conducted. The only factor having a significant impact was the lack of precision around the 
efficacy estimates. The relative risks for the outcomes of death and death or dependency 
were not statistically significant in the 3 to 4.5 hour onset to treatment window. Applying the 
upper and lower 95% confidence intervals for both these parameters as point estimates within 
the model resulted in a large variation in the ICER.  The cost-effectiveness estimates for the 0 
to 4.5 hour onset to treatment window were similarly sensitive to uncertainty in the efficacy 
estimates. All of the sensitivity analyses which examined the use of alternative efficacy 
estimates incorporating ad-hoc subgroup analyses from either the ATLANTIS trials (0 to 3 
hour and 3 to 4.5 hour treatment window) or the ECASS II trial (3 to 4.5 hour treatment 
window) resulted in a decrease in both the QALYs gained and the costs accrued for alteplase 
compared to the basecase analysis, although none resulted in an ICER greater than £10,000 
per QALY. 
4.2.1. Critique of cost-effectiveness evidence and interpretation  
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The economic model described in the MS is considered by the ERG to meet the NICE 
reference case [25]. The health states included in the model were considered to be 
appropriate to capture both the treatment effect of alteplase on stroke severity and the impact 
of SICH following thrombolytic therapy. The evidence used to populate the transition 
probabilities were considered to be relevant to the UK population. The data from the LRS 
which are used to determine the health state distribution in the standard care arm are now 
over 10 years old and may not reflect recent improvements in stroke outcomes following the 
introduction of specialist stroke units. However, any more recent source is likely to be 
confounded by improvements resulting from the use of alteplase and would therefore not be a 
suitable source of natural history data for the standard care arm. The costs and utility values 
applied to the health states were considered to be appropriate and in-keeping with the 
reference case. The cost-effectiveness estimates were generally robust under the univariate 
sensitivity analyses conducted with the main cause of decision uncertainty relating to the 
precision around the efficacy estimates. The PSA was found to sample independently from 
the relative risks for death and death or dependency, which ignores the correlation that is 
likely to exist between these two variables. This may mean that it does not provide an 
accurate description of the uncertainty around the mean costs and QALYs, although the ERG 
considers it unlikely that this would have a significant impact on the ICER.  
The ERG considers that it was appropriate to conduct separate analyses for the sub-
population of patients who are eligible for treatment within 0 to 3 hours and for the sub-
population who are eligible for treatment within 3 to 4.5 hours. The efficacy estimates for 
these two sub-populations suggest that the balance of risks and benefits may be slightly 
different and these differences in efficacy translate into differing cost-effectiveness estimates, 
even though the confidence intervals for the efficacy estimates are overlapping and there is 
no significant heterogeneity between the two treatment windows. Furthermore, neither sub-
population has a central ICER estimate above £20,000 per QALY. 
The ERG used the submitted models to estimate the global expected value of perfect 
information (EVPI) for each of the three treatment time windows using a willingness to pay 
threshold of £20,000 per QALY. The population eligible for treatment over a 5 year period was 
estimated to be 85,500, 65,400 and 20,100 within 0 to 4, 0 to 3 and 3 to 4.5 hours of symptom 
onset, respectively. The estimated population global EVPI was £324,000, £6,593,000 and 
£5,119,000, for treatment within 0 to 4.5, 0 to 3 and 3 to 4.5 hours, respectively. The 
population global EVPI was estimated to be much higher when considering the 0 to 3 hour 
and 3 to 4.5 hour time windows separately as there is greater uncertainty in the RRs for death 
and death or dependency when considering just those studies which are applicable to each 
sub-population. 
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5. &RQFOXVLRQVRIWKH(5*UHSRUW 
The ERG had no major concerns regarding the completeness of the submission or the 
robustness of the evidence presented. The evidence presented in the MS reflects the 
decision problem identified in the scope. The analyses presented were restricted to 
participants for whom alteplase was administered within 4.5 hours of symptom onset, and so 
this accurately reflected the NICE scope [12]. 
The RCTs included were generally of good quality with regard to randomisation and having 
blinded outcome assessors. Trial data from ad-hoc subgroup analyses which do not represent 
a true randomised comparison were excluded from the main results and only considered in 
sensitivity analyses. The main area of uncertainty with regard to clinical effectiveness related 
to differences in stroke severity at baseline, which potentially favoured alteplase, in two of the 
three key trials.  
The economic model described in the MS is considered by the ERG to meet the NICE 
reference case. The model structure was considered to be appropriate and the ERG has no 
major concerns regarding the selection of data used within the model. In the cost-
effectiveness analysis the main driver of decision uncertainty was the lack of precision around 
the efficacy estimates. 
6. .H\PHWKRGRORJLFDOLVVXHV  
The main area of uncertainty with regard to clinical effectiveness relates to differences in 
stroke severity at baseline, which potentially favour alteplase, in two of the three key trials.  
In the cost-effectiveness analysis the main driver of decision uncertainty is the lack of 
precision around the efficacy estimates. The amount of decision uncertainty, represented by 
the global population EVPI, is dependent on whether one considers the cost-effectiveness of 
the whole population covered by the licensed indication or whether one looks separately at 
the subpopulations able to receive alteplase within 0 to 3 hours and 3 to 4.5 hours from 
symptom onset. Combining data across the two treatment windows increases the precision of 
the efficacy estimates but also ignores any variation in the balance of risks and benefits that 
may exist within the licensed population. Alteplase was considered by the appraisal 
committee to represent an effective use of NHS resources across both subpopulations as it 
either dominated standard care or had a low ICER compared to standard care depending on 
the treatment window considered. In this situation, the decision regarding whether to 
recommend alteplase is not dependent oQ WKH FRPPLWWHH¶V judgement regarding the 
appropriateness of pooling data across the two treatment windows, but the EVPI across the 
whole licensed population is still dependent on this judgement. 
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7. 1,&(JXLGDQFH  
After considering the available evidence from the manufacturer, ERG, expert testimony and 
other submissions, the NICE appraisal committee issued the following guidance in September 
2012:  
Alteplase is recommended within its marketing authorisation for treating acute ischaemic 
stroke in adults if: 
x treatment is started as early as possible within 4.5 hours of onset of stroke 
symptoms, and 
x intracranial haemorrhage has been excluded by appropriate imaging techniques. 
 
7.1. Consideration of the evidence 
The main areas discussed by the Committee and recorded in the Final Appraisal 
Determination along with the recommendations of the Committee are summarized in the 
following sections. 
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of 
alteplase, having considered evidence on the nature of acute ischaemic stroke and the value 
placed on the benefits of alteplase by people with the condition, those who represent them, 
and clinical specialists. It also took into account the effective use of NHS resources. 
The Committee considered the evidence submitted by the manufacturer on the clinical 
effectiveness of alteplase. The Committee noted that no clinical-effectiveness data for the 0 to 
3-hour treatment window additional to those included in NICE technology appraisal guidance 
TA122 were available, and that clinical-effectiveness data for the 3 to 4.5-hour treatment 
window were derived primarily from the ECASS III trial. The Committee considered 
methodological issues concerning the ECAS lll trial and concluded that this trial was of good 
methodological quality and provided robust evidence of the clinical efficacy of alteplase for the 
3 to 4.5-hour treatment window. 
The Committee considered the clinical effectiveness of alteplase for the 3 to 4.5-hour 
treatment window. The Committee concluded that alteplase administered between 3 and 
4.5 hours after onset of stroke symptoms was an effective treatment for acute ischaemic 
stroke because it decreased the probability of disability. 
The Committee considered the manufacturer's meta-analyses, which generated alternative 
estimates of alteplase's effect on all cause mortality and also on death or dependence (mRS 
score of 3 to 6) at 90 days for each of the 3 treatment windows (0 to 3 hours, 3 to 4.5 hours, 
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and 0 to 4.5 hours), and which were used for the clinical-effectiveness parameters in the 
manufacturer's economic model. The Committee noted that the trials included in the meta-
analyses for the 0 to 4.5-hour treatment window were of good methodological quality and 
were sufficiently similar in terms of study design and results. The Committee concluded that 
alteplase administered between 0 and 4.5 hours after onset of stroke symptoms was an 
effective treatment for acute ischaemic stroke because it decreased the probability of death or 
dependence. 
The Committee considered the evidence on adverse reactions associated with alteplase. The 
Committee noted that a significantly higher proportion of patients in the alteplase arm had 
SICH within 10 days compared with the placebo arm for the 3 to 4.5-hour window in the 
ECASS III trial and for the 0 to 4.5-hour window in the manufacturer's meta-analyses. 
However, the Committee noted that while alteplase increased the risk of SICH, the absolute 
number of patients in the ECASS III trial who had a SICH was small. The Committee heard 
from the clinical specialists that SICH is the primary cause of death within 7 days for patients 
receiving alteplase treatment, and that clinicians have difficulty predicting which patients are 
at high risk. The Committee also noted that the proportion of other reported serious adverse 
reactions and fatal adverse reactions in the ECASS III trial up to 90 days was similar across 
the 2 treatment arms. The Committee concluded that, although the increased risk of SICH 
associated with alteplase is offset by significant improvements in favourable outcomes at 
90 days, SICH is an adverse event that needs to be included in modelling of the cost 
effectiveness of alteplase. 
The Committee considered the manufacturer's economic model, the assumptions on which 
the parameters were based, and the critique and exploratory analyses conducted by the 
ERG. The Committee noted that the model structure and many of the input parameters were 
identical to those used in the economic model for NICE technology appraisal guidance TA122 
(0 to 3-hour window) and agreed that this approach was appropriate. With regard to the 
clinical-effectiveness parameters used in the model, the Committee acknowledged that the 
survival benefit associated with alteplase compared with standard care, which resulted from a 
point estimate for the relative risk for alteplase treatment and death of less than 1, was 
appropriately reflected in the economic model. However, the Committee noted that the 
manufacturer had assumed that the relative treatment effect of alteplase was maintained 
beyond 90 days up to 6 months in the model with no longer-term survival benefit beyond this 
point. The Committee considered that this may have been a conservative approach if 
alteplase offers a survival advantage compared with placebo beyond 6 months, a proposition 
the Committee found plausible, although not currently proven statistically, given that alteplase 
was associated with a reduction in death or dependence at 90 days. The Committee was 
aware that the utility values were not adjusted over time in the model, which may have 
overestimated the QALYs accrued by people in the independent health state and therefore 
biased the results in favour of alteplase. However, the Committee considered that this was 
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not a crucial limitation of the model because the ICERs were not sensitive to changes in the 
utility values in the manufacturer's sensitivity analyses, and therefore any downward 
adjustment over time would have had a small impact on the ICERs. The Committee was also 
aware that the manufacturer assumed that people who had a SICH in the economic model 
incurred the additional one-off cost of a CT scan but experienced no further disutility beyond 
that captured in the dependent or independent health states. The Committee heard from the 
clinical specialists that this assumption was reasonable. Overall, the Committee concluded 
that the economic model adhered to the NICE reference case for economic analysis and the 
modelling approach was reasonable. 
The Committee considered the most plausible ICERs presented by the manufacturer and also 
by the ERG in its exploratory analyses. It agreed that alteplase either dominated standard 
care or had an ICER below £10,000 per QALY gained depending on the time-to-treatment 
window considered. The Committee noted that none of the additional exploratory analyses 
undertaken by the ERG resulted in ICERs that varied substantially from those presented in 
the MS.  
The Committee also agreed with the clinical specialists that extending the time window for 
treatment should not diminish the urgency with which people suspected of having an acute 
ischaemic stroke should be treated.  
The Committee discussed whether any equality issues required consideration in this 
appraisal. The Committee was aware that extension of the licence to 4.5 hours after symptom 
onset may enable increased access to treatment with alteplase for patients in remote or rural 
locations. 
8. &RQFOXVLRQ  
The Committee concluded that alteplase administered between 3 and 4.5 hours after onset of 
stroke symptoms was an effective treatment for acute ischaemic stroke because it decreased 
the probability of disability. 
The Committee concluded that alteplase administered between 0 and 4.5 hours after onset of 
stroke symptoms was an effective treatment for acute ischaemic stroke because it decreased 
the probability of death or dependence. 
The Committee agreed that alteplase either dominated standard care or had an ICER below 
£10,000 per QALY gained depending on the time-to-treatment window considered. The 
Committee concluded that treating acute ischaemic stroke with alteplase within 0 to 4.5 hours 
of onset of stroke symptoms was a cost-effective use of NHS resources. 
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